HEALTH & FOOD / DISTRIBUTED

INFRAFRONTIER

European Research Infrastructure for Modelling Human Diseases
General Info
headquarters

INFRAFRONTIER ERIC

Munich, Germany

legal status
type

distributed

access

remote

description
INFRAFRONTIER, the European Research Infrastructure for Modelling Human Diseases, stands as a pillar of collaborative effort and scientific excellence in the pursuit of understanding, prevention, and treatment of human diseases through cutting-edge models. The infrastructure is a non-profit entity comprising over 20 leading biomedical research institutes distributed across 15 countries: 13 of them in Europe (Austria, Czech Republic, Denmark, Finland, France, Germany, Greece, Italy, Netherlands, Portugal, Spain, Sweden, and United Kingdom), plus Israel and Canada. The INFRAFRONTIER GmbH, established in 2013 as a private limited company in Munich, Germany, is the coordination unit and central hub of the distributed INFRAFRONTIER Research Infrastructure. This task in now taken over by the INFRAFRONTIER ERIC, which was established by the European Commission in December 2023 with Germany, Czech Republic, Finland, France, Greece, and Sweden as Founding Members. In basic and preclinical biomedical research, the identification of the genetic effects on human disease is a key goal, and the investigation of gene function through appropriate models is a central element in achieving this aim. Here is where the need for an infrastructure like INFRAFRONTIER arises, which, through the operation of the largest mouse repository in Europe, the European Mouse Mutant Archive (https://www.infrafrontier.eu/emma/), offers cryopreservation and distribution of rodent models across and beyond the continent. Moreover, INFRAFRONTIER conducts comprehensive systemic phenotyping of mouse lines and develops new disease models, including germ-free rodent lines intended for gnotobiotic studies and new approach methodologies (NAMs), like in-vitro models. INFRAFRONTIER's service portfolio is continuously expanding, and experts diligently update and curate data on the website to guide academia and industry scientists in selecting the best model to develop groundbreaking therapies. The commitment to excellence and innovation is realised through INFRAFRONTIER's partners; professionals trained in the latest technology and standardised protocols that prioritise animal welfare and drive the 3Rs – replacement, reduction, and refinement – in animal research. INFRAFRONTIER also offers a wide range of courses and training opportunities aimed at researchers and technical staff at any stage of their professional careers. Some examples include workshops on cryopreservation, genetic diseases, and gene editing. INFRAFRONTIER actively collaborates with other Research Infrastructures to enable global access to research data and infrastructures, thereby accelerating the acquisition of knowledge and technological advancements in the field of human health. INFRAFRONTIER also engages with policy makers and funders to align science policy agendas and provide input to societal issues such as animal welfare and the 3Rs.
TIMELINE & ESTIMATED COSTS
Total Investment 180 M€ Design Preparation Implementation Operation 80 M€/year Project Landmark 2006 2008 2010 2012 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 2034 2036 2038 RM06 RM08 RM10 RM16 RM18 RM21 LA24
Roadmap Entry
as project: 2006
as landmark: 2016
Total investment
180 M€
Design Phase
Preparation Phase
2008-2012
Implementation Phase
2010-2013
Operation start
2013
80 M€/year
IMPACTS
INFRAFRONTIER’s mission is to empower and support biomedical researchers by providing a comprehensive range of in vivo/in vitro model systems and related expert services. Over the last decade, INFRAFRONTIER has made significant contributions in this regard by distributing mutant mouse strains to more than 14000 users, launching more than 50 open access calls, enabling 1100 publications, and supporting more than 500 user projects. Its focus on adopting cutting-edge gene editing technologies, standardising and improving cryopreservation and phenotyping processes, launching challenge-driven services, and promoting FAIR data principles has bolstered disease modelling activities in Europe and global competitiveness of the European Research Area. INFRAFRONTIER supports a bottom-up approach for individual scientists and research groups and provides top-down capacities for large-scale international initiatives such as the International Mouse Phenotyping Consortium (IMPC) along with a wide range of state-of-the-art training opportunities and consulting services. By offering affordable and easily accessible disease modelling services, INFRAFRONTIER has catalysed research in understanding fundamental scientific questions related to human health and disease. This initiative along with long-term commitment to animal welfare, sustainability of databases and repositories has not only strengthened the European Research Infrastructure landscape but has also fostered collaborations between universities, research institutes, and the biomedical industry, thus reinforcing the foundation of biomedical research in Europe.
SERVICES
INFRAFRONTIER provides a wide range of resources and services on a non-profit basis: Rodent Model Archiving and Distribution: INFRAFRONTIER accepts submissions of mutant mouse and rat strains from all over the world for their cryopreservation and further distribution within the research community. The Infrastructure operates EMMA, the largest mouse repository in all Europe (ranking third worldwide). More information at https://www.infrafrontier.eu/emma/ Precision Model Generation: INFRAFRONTIER offers the development of new models to study gene function, allowing researchers that lack the necessary expertise and technology to create rodent models that precisely mimic the genetic perturbations in human disease. More information at https://www.infrafrontier.eu/services/rodent-model-generation/ Systemic Phenotyping: INFRAFRONTIER performs a systemic, multi-organ phenotypic analysis of strains of interest thanks to the expertise of its partner institutes, world leaders in systemic phenotyping. More information at https://www.infrafrontier.eu/services/systemic-phenotyping/ Axenic Service: INFRAFRONTIER offers the generation of germ-free mice to study the effects of microbiota in living organisms, saving time and money for researchers. More information at https://www.infrafrontier.eu/services/axenic-service/ Other resources and services provided by the infrastructure are Development of New Approach Methodologies (NAMs), Disease Model Data Curation, and Consultancy Services. Further details at https://www.infrafrontier.eu/services/
Interconnections
INFRAFRONTIER
S S H D I G I T E N E E N V P S E
COOPERATION WITH OTHER RIs
INFRAFRONTIER has established long-standing collaborations with all Life-Science Research Infrastructures (LS-RIs: ANAEE, BBMRI, EATRIS, ECRIN, ELIXIR, EMBL, EMBRC, EMPHASIS, ERINHA, EU-OPENSCREEN, EURO-BIOIMAGING, IBISBA, INSTRUCT, MIRRI). Besides participating in EC-projects to harmonise service provision, research data and training activities and link them to the European Open Science Cloud (BioMedBridges, EMTRAIN, CORBEL, EOSC-Life) or to provide services for societal health challenges (EJP-RD for rare diseases research, ISIDORe and BY-COVID for infectious diseases, canSERV and EOSC4Cancer for cancer research) and the LS-RIs also develop common scientific and stakeholder engagement strategies under a common Memorandum of Understanding. INFRAFRONTIER has also established collaborations with Research Infrastructures from other scientific domains (GEANT, EGI, CERN, EISCAT, SHARE, ESS, CESSDA, EMSO, INTERACT, LEAPS consortium) to set specifications for authentication and authorisation infrastructure (AARC2 project), training Research Infrastructure management (RItrain), international visibility (RI-VIS) and remote access (eRImote).